Recent Developments in Argenx SE
Earnings and Revenue Growth
On 22 October 2026, Argenx SE reported its third‑quarter results, showing a significant increase in both revenue and earnings.
- Revenue rose by 54 % year‑over‑year to $1.7 billion (≈ €1.53 billion), driven largely by sales of the autoimmune drug Vyvgart.
- Net income attributable to owners increased to $506 million from $344 million a year earlier.
- Earnings per share climbed to $7.80 versus $5.18 last year.
- Operating profit grew from $346 million to $486 million.
These figures reflect a continued upward trajectory for the company’s flagship product and underscore its position within the severe autoimmune disease market.
Market Reaction and Analyst Outlook
Despite the robust financial performance, market expectations for higher profitability remained unmet. As a result, the share price, while still in positive territory, did not fully recover from a recent research‑related dip. In response:
| Analyst | Action | New Target | Rationale |
|---|---|---|---|
| Guggenheim | Reduced price target | $1,120 | Model revision |
| Baird | Raised price target | $861 | Strong Vyvgart sales |
| Jefferies | Maintained “Buy” rating | – | Strong Q3 results |
| Stifel | Lowered price target | – | Mixed quarterly results |
| TD Cowen | Reiterated “Buy” rating | – | Vyvgart strength |
The consensus remains positive, with most analysts retaining a “Buy” recommendation while adjusting their targets to reflect the latest earnings data and market sentiment.
Product Performance
Vyvgart continues to be the company’s primary revenue driver. In the third quarter, global sales increased by 54 %, reinforcing its market position against competitors in the generalized myasthenia gravis segment. The drug’s performance has been described as a “mighty boost” for the company, although analysts note that further growth will depend on continued patient reach and potential market expansion.
Strategic Implications
Argenx’s focus on antibody‑based therapies for severe autoimmune diseases and cancer is supported by the recent Q3 results. The company’s continued investment in research and development, combined with its strong sales pipeline, positions it well for future expansion. However, the firm must manage research and sales costs carefully to meet or exceed market earnings expectations.
Conclusion
Argenx SE’s third‑quarter earnings demonstrate significant revenue growth and profitability improvement, primarily driven by Vyvgart sales. While analyst targets have been adjusted, the overall market view remains supportive, reflecting confidence in the company’s product portfolio and strategic direction.
